Benchmark Holdings plc
("Benchmark" or the "Company")
Listing of Green NOK Bond
Listing of ISIN NO0012704099 - Benchmark Holdings PLC FRN senior unsecured green NOK 750,000,000 bonds 2022/2025 (the "Bond")
12 April 2023
Benchmark, the aquaculture biotechnology company, notifies that further to the announcement made on 16 September 2022, the Company has today listed its Bond on the Oslo Stock Exchange. As previously announced, the Bond has a coupon of three months NIBOR* + 6.5% p.a. with quarterly interest payments and is expected to mature on 27 September 2025.
A copy of the prospectus, which was approved by the NFSA, the Norwegian Financials Supervisory Authority, on 31 March 2023, and the final terms of the Bond, are available at https://www.benchmarkplc.com/investors/documents-circulars/#documents
*The three-month NIBOR (Norwegian Interbank Offered Rate) stood at 3.63% as at 23 March 2023.
Enquiries
For further information, please contact: |
|
Benchmark Holdings plc |
Tel: 0114 240 9939 |
Ivonne Cantu, Investor Relations |
|
Numis (Broker and NOMAD) |
Tel: 020 7260 1000 |
James Black, Freddie Barnfield, Duncan Monteith |
|
MHP |
Tel: 020 3128 8004 |
Katie Hunt, Reg Hoare, Veronica Farah |
|
About Benchmark
Benchmark is a market leading aquaculture biotechnology company. Benchmark's mission is to drive sustainability in aquaculture by delivering mission-critical products and solutions in genetics, advanced nutrition and health which improve yield, growth and animal health and welfare. Through a global footprint in 26 countries and a broad portfolio of products and solutions, Benchmark addresses the major aquaculture species - salmon, shrimp, sea bass and bream, and tilapia, in all the aquaculture regions around the world.
Find out more at www.benchmarkplc.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. ENDMSCSSDFLIEDSEEL
==